Carcinoma marker Inhibitors
Carcinoma Marker inhibitors are a broad range of chemical compounds that act on various signaling pathways, ultimately leading to a decrease in Carcinoma Marker activity. The inhibitors Genistein, U0126, Quercetin, LY294002, PD98059, Wortmannin, Apigenin, Resveratrol, EGCG, SB203580, SP600125, and Curcumin all act on different pathways that Carcinoma Marker is thought to interact with, including the EGFR, ERK, PI3K/AKT, JNK, and p38 MAPK pathways. When these pathways are inhibited, they can lead to decreased Carcinoma Marker activity.
Genistein, a tyrosine kinase inhibitor, acts on the EGFR pathway. Since Carcinoma Marker is involved in this pathway, Genistein's inhibition can lead to a decrease in Carcinoma Marker activity. U0126, a MEK1/2 inhibitor, targets the ERK pathway. With Carcinoma Marker interacting with the ERK pathway, its inhibition can lead to decreased Carcinoma Marker activity. Quercetin, LY294002, Wortmannin, Apigenin, Resveratrol, and EGCG are all PI3K inhibitors, and since Carcinoma Marker is involved in the PI3K/AKT pathway, their inhibition of this pathway can lead to decreased Carcinoma Marker activity. PD98059 acts similarly to U0126, inhibiting the ERK/MAPK pathway, and thus, can cause a decrease in Carcinoma Marker activity. SB203580, an inhibitor of p38 MAPK, can also decrease Carcinoma Marker activity due to its involvement with the p38 MAPK pathway. SP600125, a JNK signaling inhibitor, and Curcumin, an inhibitor of both the JNK and p38 MAPK signaling pathways, can lead to decreased Carcinoma Marker activity due to its interaction with these pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor, specifically inhibiting EGFR. Carcinoma Marker is involved in EGFR signaling pathway. Therefore, the inhibition of this pathway by Genistein can lead to a decrease in Carcinoma Marker activity. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $108.00 $245.00 $918.00 $49.00 | 33 | |
Quercetin is a PI3K inhibitor. Carcinoma Marker is involved in the PI3K signaling pathway. Therefore, the inhibition of PI3K by Quercetin can cause a decrease in Carcinoma Marker activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, which is crucial in the PI3K/AKT signaling pathway. As Carcinoma Marker is involved in this pathway, LY294002 can lead to decreased Carcinoma Marker activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor, specifically inhibiting the ERK/MAPK pathway. Carcinoma Marker is involved in the ERK/MAPK pathway, so its inhibition by PD98059 can lead to decreased Carcinoma Marker activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor. Carcinoma Marker is involved in the PI3K signaling pathway. Therefore, the inhibition of this pathway by Wortmannin can lead to a decrease in Carcinoma Marker activity. | ||||||
Apigenin | 520-36-5 | sc-3529 sc-3529A sc-3529B sc-3529C sc-3529D sc-3529E sc-3529F | 5 mg 100 mg 1 g 5 g 25 g 100 g 1 kg | $32.00 $210.00 $720.00 $1128.00 $2302.00 $3066.00 $5106.00 | 22 | |
Apigenin inhibits PI3K/AKT pathway, which Carcinoma Marker is involved in. Therefore, the inhibition of this pathway by Apigenin can lead to a decrease in Carcinoma Marker activity. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol inhibits the PI3K/AKT pathway. Since Carcinoma Marker is involved in this pathway, Resveratrol's inhibition of the PI3K/AKT pathway can lead to decreased Carcinoma Marker activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG inhibits the PI3K/AKT pathway. As Carcinoma Marker is involved in this pathway, EGCG's inhibition of the PI3K/AKT pathway can lead to decreased Carcinoma Marker activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK. Carcinoma Marker is involved with the p38 MAPK pathway, and inhibition of this pathway by SB203580 can lead to a decrease in Carcinoma Marker activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK signaling. As Carcinoma Marker is thought to interact with the JNK pathway, its inhibition by SP600125 can lead to a decrease in Carcinoma Marker activity. | ||||||